1. Scrip
  2. >>New Products

Budesonide CRL Another Setback For Takeda’s ‘Wave 1’ Pipeline

 
• By Ian Haydock

Setback for company's near-term launch goals and US patients with rare esophageal inflammatory condition as regulator asks for additional clinical data. 

esophagitis
US FDA Decides Not To Approve First Drug For Eosinophilic Esophagitis • Source: Alamy

Takeda Pharmaceutical Co. Ltd. has received a Complete Response Letter (CRL) from the US Food and Drug Administration for its 2020 new drug application for Eohilia (TAK-721), an oral suspension of the corticosteroid budesonide for eosinophilic esophagitis (EoE).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 
• By Andrew McConaghie

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.